FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in individuals with CKD.
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in individuals with CKD.
What's Your Reaction?
